A detailed history of Chi Advisors LLC transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Chi Advisors LLC holds 3,414,189 shares of CGEM stock, worth $40.5 Million. This represents 15.23% of its overall portfolio holdings.

Number of Shares
3,414,189
Previous 3,414,189 -0.0%
Holding current value
$40.5 Million
Previous $36.7 Million 15.89%
% of portfolio
15.23%
Previous 13.81%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$8.8 - $13.4 $569,615 - $867,368
64,729 Added 1.93%
3,414,189 $36.7 Million
Q1 2023

May 11, 2023

BUY
$10.2 - $11.91 $325,543 - $380,119
31,916 Added 0.96%
3,349,460 $34.3 Million
Q4 2022

Feb 13, 2023

BUY
$9.72 - $13.62 $722,769 - $1.01 Million
74,359 Added 2.29%
3,317,544 $35 Million
Q3 2022

Nov 09, 2022

BUY
$11.82 - $15.42 $2.31 Million - $3.02 Million
195,576 Added 6.42%
3,243,185 $41.6 Million
Q2 2022

Aug 12, 2022

BUY
$7.31 - $13.55 $2.15 Million - $3.99 Million
294,562 Added 10.7%
3,047,609 $39.1 Million
Q1 2022

May 16, 2022

BUY
$10.47 - $16.75 $2.89 Million - $4.63 Million
276,327 Added 11.16%
2,753,047 $28.8 Million
Q4 2021

Feb 11, 2022

BUY
$15.36 - $25.0 $3.56 Million - $5.8 Million
231,879 Added 10.33%
2,476,720 $38.2 Million
Q3 2021

Nov 15, 2021

BUY
$22.56 - $29.68 $45,120 - $59,360
2,000 Added 0.09%
2,244,841 $50.7 Million
Q2 2021

Aug 11, 2021

BUY
$24.96 - $41.25 $1.01 Million - $1.67 Million
40,434 Added 1.84%
2,242,841 $57.8 Million
Q1 2021

May 14, 2021

BUY
$28.0 - $53.42 $61.7 Million - $118 Million
2,202,407 New
2,202,407 $91.8 Million

Others Institutions Holding CGEM

About Cullinan Oncology, Inc.


  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $541M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Chi Advisors LLC Portfolio

Follow Chi Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Chi Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Chi Advisors LLC with notifications on news.